摘要
目的:探讨异体淋巴细胞输注防治白血病造血干细胞移植(HSCT)后复发的疗效及安全性。方法:回顾性研究2000年2月至2010年4月间在南方医科大学珠江医院行HSCT后进行异体淋巴细胞输注的35例白血病患者,包括20例自体造血干细胞移植(Auto-HSCT)患者和15例异基因造血干细胞移植(Allo-HSCT)患者。结果:35例患者3年总生存(OS)率为43.3%,3年无病生存(DFS)率为38.9%。Auto-HSCT患者行异体淋巴细胞输注患者的3年OS为63.2%,3年DFS为55.0%。而Allo-HSCT患者复发后行治疗性输注的患者完全缓解率(CR)仅为35.7%,3年OS为10.0%。患者死亡原因主要是疾病复发(17例)、骨髓抑制(1例)及急性GVHD(1例)等。结论:异体淋巴细胞输注是防治移植后复发的有效方法,高复发风险的患者行预防性输注有望提高生存期,且异体淋巴细胞输注相关副作用无明显增加。
Objective: This study aims to investigate the efficacy and safety of allogenic lymphocyte transfusion (ALT) for the prevention and treatment of relapsed leukemia after hematopoietic stem cell transplantation (HSCT). Methods: Data of 35 consecutive leukemia patients receiving ALT in our hospital from 2000 to 2010 were retrospectively studied, among which 20 were receiving auto-HSCT and 15 were receiving allo-HSCT. Results: The three-year overall survival (OS) and disease-free survival (DFS) were 43.3% and 38.9%, respectively in all patients. In the auto-HSCT patients mainly undergoing preventative ALT, the three-year OS and DFS were 66.8% and 62.3%, respectively, whereas the complete remission and three-year OS for the allo-HSCT patients mainly receiving allo-HSCT were only 35.7% and 10.0%, respectively. The main cause of death in these patients included relapse of the disease (n=17), bone marrow inhibition _(n=1), and acute graft-versus-host disease (n=1). Conclusion: ALT is an effective therapy for the prevention and treatment of relapsed leukemia. Preventative allo-HSCT may significantly improve the survival time for high-risk patients, without overt increase of treat ment-related mortality.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第23期1934-1938,共5页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金(编号:30500607)
教育部新世纪优秀人才支持计划(编号:NCET-09-0087)
教育部留学回国人员科研启动基金
广东省自然科学基金重点项目(编号:9251051501000007)
广州市科技计划重点项目(编号:12C22121595)资助~~
关键词
白血病
造血干细胞移植
异体淋巴细胞输注
复发
Leukemia
Hematopoietic stem cell transplantation
Lymphocyte transfusion
Relapse